Evaluation of the efficacy and safety of first- and second-line immunotherapy in patients with metastatic colorectal cancer: a systematic review and network meta-analysis based on randomized controlled trials

医学 随机对照试验 荟萃分析 结直肠癌 微卫星不稳定性 子群分析 内科学 肿瘤科 免疫疗法 科克伦图书馆 梅德林 癌症 等位基因 生物化学 化学 政治学 法学 微卫星 基因
作者
Kaiqi Chen,Hao Chen,Rui Yue,Danping Zhu,Shikui Cui,Xijian Zhang,Jin Zhao,Tong Xiao
出处
期刊:Frontiers in Immunology [Frontiers Media]
卷期号:15
标识
DOI:10.3389/fimmu.2024.1439624
摘要

Background A multitude of randomized controlled trials (RCTs) conducted in both the initial and subsequent treatment settings for patients diagnosed with metastatic colorectal cancer (mCRC) have provided clinical evidence supporting the efficacy of immunotherapy with the use of immune checkpoint inhibitors (ICIs). In light of these findings, the U.S. Food and Drug Administration (FDA) has authorized the use of several ICIs in specific subpopulations of mCRC patients. Nevertheless, there remains a dearth of direct comparative RCTs evaluating various treatment options. Consequently, the most effective ICI therapeutic strategy for microsatellite-stable (MSS) subgroup and microsatellite instability (MSI) subgroup in the first- and second-line therapies remains undefined. To address this gap, the present study employs a Bayesian network meta-analysis to ascertain the most effective first- and second-line ICI therapeutic strategies. Methods A comprehensive literature search was conducted across multiple databases, including PubMed, EMBASE, Cochrane Library, and Web of Science, with the retrieval date ranging from the databases’ inception to August 20, 2024. A total of 875 studies were identified, and seven were ultimately included in the analysis after a screening process. A systematic review and network meta-analysis were conducted on the basis of the search results. Results This comprehensive analysis, comprising seven RCTs, evaluated first-line and second-line immunotherapy regimens in 1,358 patients diagnosed with mCRC. The treatments under investigation consisted of five initial treatments, including three focusing on MSS patients and two on MSI patients, as well as two secondary immunotherapy regimens, both focusing on MSS patients. A total of 1051 individuals underwent first-line treatment, while 307 received second-line treatment. The application of ICIs proved to offer varying degrees clinical benefits when compared to standard-of-care therapy alone, both in two subgroups of the first and the second treatment phases. Of particular note is the performance of Nivolumab combination with ipilimumab, which demonstrated superior efficacy in improving progression-free survival (PFS) (HR=0.21; 95% CI, 0.13-0.34),. Moreover, the treatment demonstrated an optimal safety profile, with a relatively low risk of adverse events (OR = 0.33; 95% CI, 0.19–0.56), compared to other first-line treatment modalities for MSI subgroup. Regarding MSS subgroup, the improvement of PFS by Nivolumab plus standard-of-care (SOC) was relatively significant (HR = 0.74; 95% CI, 0.53-1.02). In the realm of second-line therapies for MSS subgroup, the administration of Atezolizumab plus SOC has proven to be an effective approach for prolonging PFS, exhibiting an HR of 0.66 (95% CI, 0.44–0.99). These findings underscore the clinical benefits and safety profiles of ICIs in the treatment of mCRC across various treatment lines. Conclusions The clinical application of ICIs in both first- and second-line treatment strategies for patients with mCRC yields substantial therapeutic benefits. A detailed assessment in this study indicates that first-line treatment with Nivolumab combination with ipilimumab may represent an efficacious and well-tolerated therapeutic approach for MSI subgroup. In terms of MSS subgroup in first-line therapy, Nivolumab plus SOC may be a relative superior choice. In the context of second-line therapy for MSS subgroup, it is evident that a combination of Atezolizumab and SOC represents a preferable option for enhancing PFS. Furthermore, it is noteworthy that other ICIs treatment regimens also exhibit great value in various aspects, with the potential to inform the development of future clinical treatment guidelines and provide a stronger rationale for the selection of ICIs in both first- and second-line therapeutic strategies for mCRC. Systematic review registration https://www.crd.york.ac.uk/prospero/#recordDetails , identifier CRD42024543400.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
英姑应助大橙子采纳,获得10
3秒前
普鲁卡因发布了新的文献求助10
5秒前
积极的帽子完成签到 ,获得积分10
5秒前
量子星尘发布了新的文献求助10
7秒前
现代冷松完成签到,获得积分10
10秒前
Chimmy完成签到,获得积分10
15秒前
朴树朋友完成签到,获得积分20
15秒前
wlnhyF完成签到,获得积分10
17秒前
pursuit完成签到,获得积分10
20秒前
Neltharion完成签到,获得积分10
21秒前
沈海完成签到,获得积分10
23秒前
悦耳傥完成签到 ,获得积分10
23秒前
一叶知秋应助大橙子采纳,获得10
23秒前
科研小能手完成签到,获得积分10
24秒前
guoxingliu发布了新的文献求助200
25秒前
Double_N完成签到,获得积分10
28秒前
路路完成签到 ,获得积分10
29秒前
碧蓝的盼夏完成签到,获得积分10
33秒前
AU完成签到 ,获得积分10
34秒前
研友_yLpYkn完成签到,获得积分10
35秒前
兴奋的定帮完成签到 ,获得积分0
36秒前
一叶知秋应助大橙子采纳,获得10
37秒前
38秒前
金蛋蛋完成签到 ,获得积分10
38秒前
马琛尧完成签到 ,获得积分10
40秒前
一行白鹭上青天完成签到 ,获得积分10
44秒前
帅气的宽完成签到 ,获得积分10
45秒前
lixoii完成签到 ,获得积分10
47秒前
萌萌许完成签到,获得积分10
47秒前
sunce1990完成签到 ,获得积分10
50秒前
Bin_Liu完成签到,获得积分20
51秒前
宇老师完成签到,获得积分10
51秒前
研友_VZG7GZ应助马琛尧采纳,获得10
52秒前
安安的小板栗完成签到,获得积分10
55秒前
123_完成签到,获得积分10
57秒前
NexusExplorer应助大橙子采纳,获得10
58秒前
上善若水完成签到 ,获得积分10
1分钟前
qiqi发布了新的文献求助10
1分钟前
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038157
求助须知:如何正确求助?哪些是违规求助? 3575869
关于积分的说明 11373842
捐赠科研通 3305650
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022